U.S., April 18 -- ClinicalTrials.gov registry received information related to the study (NCT07537972) titled 'Denosumab Strategy for Liver Cancer With Bone Metastases' on April 12.
Brief Summary: This study will evaluate whether starting denosumab early, together with a locked uniform PD-1-based systemic therapy, can reduce skeletal-related events and delay worsening bone pain compared with a delayed/rescue bone-modifying strategy in patients with hepatocellular carcinoma and bone metastases. Participants will be randomly assigned in a 1:1 ratio to receive either early denosumab plus the same PD-1-based systemic therapy or the same systemic therapy with no routine prophylactic bone-modifying agent at baseline and rescue treatment only when...